Stockreport

OS Therapies Reports Full Year 2024 Financial Results and Provides Business Update

OS Therapies Incorporated  (OSTX) 
PDF Full data from OST-HER2 Phase 2b osteosarcoma trial, including synthetic control arm data being developed at the request of FDA to support a Breakthrough Therapy Designa [Read more]